Susceptibility of Carbapenem-Resistant Acinetobacter baumannii and Carbapenem-Resistant Klebsiella pneumoniae Against Cefiderocol with Reference to Their Genetic Profile in India
Restricted accessResearch articleFirst published online April, 2026
Susceptibility of Carbapenem-Resistant Acinetobacter baumannii and Carbapenem-Resistant Klebsiella pneumoniae Against Cefiderocol with Reference to Their Genetic Profile in India
Cefiderocol (FDC) shows promise against carbapenem resistance, with differing carbapenemase epidemiology across Southeast and East Asia, including India. This study evaluated the susceptibility of carbapenem-resistant Klebsiella pneumoniae (CRKP) and carbapenem-resistant Acinetobacter baumannii (CRAB) against FDC and assessed carbapenemase genetic influences on susceptibility. A total of 100 clinical isolates of CRAB and 100 clinical isolates of CRKP were studied. The minimum inhibitory concentration for FDC, ceftazidime–avibactam (CZA), aztreonam, polymyxins in CRKP, and polymyxins and minocycline in CRAB was determined by the broth microdilution method. Carbapenemases were detected using the ethylenediaminetetraacetic acid-modified carbapenem inactivation method in CRKP and the modified Hodge test for CRAB. The confirmation of carbapenemases (blaSME, blaNMC, blaGES, blaKPC, blaIMP, blaVIM, and blaNDM for all; blaOXA-48 in CRKP; and blaOXA-23 likeblaOXA-24/40 and blaOXA-58 in CRAB) was performed by multiplex PCR. FDC resistance in CRKP and CRAB was 1% and 6%, respectively. CRKP isolates showed significant resistance to polymyxin B (31%), colistin (21%), aztreonam (34%), and CZA (41%; p < 0.05) as compared to FDC, while CRAB isolates exhibited higher FDC resistance (p < 0.05). Moreover, 96% of CRKP and 100% of CRAB were carbapenemase producers. For CRKP, blaOXA-48 + blaNDM combination and for CRAB, blaNDM was significantly associated with FDC resistance. The study revealed the presence of blaNDM as one of the causes for reduced susceptibility to FDC in these isolates.
PierceJ, ApisarnthanarakA, SchellackN, et al.Global antimicrobial stewardship with a focus on low- and middle-income countries. Int J Infect Dis, 2020; 96:621–629; doi: 10.1016/j.ijid.2020.05.126
WHO Country Office for India. Department of Biotechnology Government of India. Indian Priority pathogen list: To guide research, discovery, and development of new antibiotics in India. World Health Organization: Geneva, Switzerland; 2021. 1–22. Available from: https://dbtindia.gov.in/sites/default/files/IPPL_final.pdf [Last accessed: May8, 2024].
4.
TilahunM, KassaY, GedefieA, et al.Emerging Carbapenem-Resistant Enterobacteriaceae infection, its epidemiology and novel treatment options: A review. Infect Drug Resist, 2021; 14:4363–4374; doi: 10.2147/IDR.S337611
5.
VeeraraghavanB, PragasamAK, BakthavatchalamYD, et al.Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India. Indian J Med Microbiol, 2018; 36(3):334–343; doi: 10.4103/ijmm.IJMM_18_326
6.
VeeraraghavanB, ShankarC, KarunasreeS, et al.Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience. Pathog Glob Health, 2017; 111(5):240–246; doi: 10.1080/20477724.2017.1340128
7.
SharmaS, BanerjeeT, KumarA, et al.Extensive outbreak of colistin resistant, carbapenemase (blaOXA-48, blaNDM) producing Klebsiella pneumoniae in a large tertiary care hospital, India. Antimicrob Resist Infect Control, 2022; 11(1):1; doi: 10.1186/s13756-021-01048-w
8.
SharmaS, BanerjeeT, YadavG, et al.Susceptibility profile of blaOXA-23 and metallo-β-lactamases co-harbouring isolates of carbapenem resistant Acinetobacter baumannii (CRAB) against standard drugs and combinations. Front Cell Infect Microbiol, 2022; 12(12):1068840; doi: 10.3389/fcimb.2022
9.
KohiraN, HackelMA, OotaM, et al.In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020. J Glob Antimicrob Resist, 2023; 32:181–186; doi: 10.1016/j.jgar.2022.11.017
10.
Uskudar-GucluA, DanyildizS, MirzaHC, et al.In vitro activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii carrying various β-lactamase encoding genes. Eur J Clin Microbiol Infect Dis, 2024; 43(6):1171–1179; doi: 10.1007/s10096-024-04831-w
11.
Santerre HenriksenA, JeannotK, OliverA, et al.ARTEMIS Study Investigators. In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations. Microbiol Spectr, 2024; 12(4):383623; doi: 10.1128/spectrum.03836-23
12.
BanerjeeT, MishraA, DasA, et al.High prevalence and endemicity of multidrug resistant acinetobacter spp. in intensive care unit of a tertiary care hospital, Varanasi, India. J Pathog, 2018; 2018:9129083; doi: 10.1155/2018/9129083
13.
FonsecaEL, RamosNV, BrunoG, et al.A one-step multiplex PCR to identify Klebsiella pneumoniae, Klebsiella variicola, and Klebsiella quasipneumoniae in the clinical routine. Diagn Microbiol Infect Dis, 2017; 87(4):315–317; doi: 10.1016/j.diagmicrobio.2017.01.005
14.
ChenTL, LeeY, KuoSC, et al.Rapid identification of Acinetobacter baumannii, Acinetobacter nosocomialis and Acinetobacter pittii with a multiplex PCR assay. J Med Microbiol, 2014; 63(Pt 9):1154–1159; doi: 10.1099/jmm.0.071712-0
15.
Clinical Laboratory and Standards Institute. “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically” in CLSI supplement M07-A9-9th edition. Clinical and Laboratory Standards Institute: Wayne, PA; 2015; p. 24. [May 7, 2024].
16.
SimnerPJ, PatelR. Cefiderocol antimicrobial susceptibility testing considerations: The Achilles’ heel of the Trojan horse? J Clin Microbiol, 2020; 59(1):e00951–e20; doi: 10.1128/JCM.00951-20
17.
ClinicalL, StandardsI. “Performance standard for antimicrobial susceptibility”. In CLSI supplement M100, 33rd edition. Table 3D: Tests for colistin resistance in Enterobactarales. Clinical and Laboratory Standards Institute: Wayne, PA; 2023; p. 174. [September 6, 2024].
18.
Clinical Laboratory and Standards Institute. “Performance standard for antimicrobial susceptibility” in CLSI supplement M100, 33rd edition. Table 3C: Modified Carbapenem Inactivation Methods for Suspected Carbapenemase Production in Enterobactarales. Clinical and Laboratory Standards Institute, Wayne, PA; 2023; p. 162. [July 6, 2024].
19.
ThirapanmetheeK. Detection of carbapenemases-producing Acinetobacter baumannii: The phenotypic approaches. Pharm Sci Asia, 2020; 47(4):319–328; doi: 10.29090/psa.2020.04.020.0100
20.
HongSS, KimK, HuhJY, et al.Multiplex PCR for rapid detection of genes encoding class a carbapenemases. Ann Lab Med, 2012; 32(5):359–361; doi: 10.3343/alm.2012.32.5.359
21.
PoirelL, WalshTR, CuvillierV, et al.Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis, 2011; 70(1):119–123; doi: 10.1016/j.diagmicrobio.2010.12.002
22.
TurtonJF, WoodfordN, GloverJ, et al.Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol, 2006; 44(8):2974–2976; doi: 10.1128/JCM.01021-06
23.
WoodfordN, EllingtonMJ, CoelhoJM, et al.Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents, 2006; 27(4):351–353; doi: 10.1016/j.ijantimicag.2006.01.004
24.
RandallLP, CoolesSW, OsbornMK, PiddockLJV, WoodwardMJ. Antibiotic resistance genes, integrons and multiple antibiotic resistance in thirty-five serotypes of salmonella enterica isolated from humans and animals in the UK’. J Antimicrob Chemother, 2004; 53(2):208–216; doi: 10.1093/jac/dkh070
25.
KohiraN, HackelMA, IshiokaY, et al.Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Resist., 2020; 22:738–741; doi: 10.1016/j.jgar.2020.07.009
26.
KarlowskyJA, HackelMA, TsujiM, et al.In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015–2016: SIDERO-WT-2015. Int J Antimicrob Agents, 2019; 53(4):456–466.
27.
ThelenP, HenriksenAS, LongshawC, et al.In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany. J Glob Antimicrob Resist, 2022; 28:12–17; doi: 10.1016/j.jgar.2021.10.029
28.
NayakG, BeheraB, MohantyS, et al.Analysis of in vitro activity of Cefiderocol against Carbapenem-Resistant gram-negative bacilli by broth microdilution and disk diffusion method: A single-center study in Odisha, India. Infect Drug Resist, 2022; 15(15):5887–5897; doi: 10.2147/IDR.S378579
29.
van LoonK, Voor In ‘t HoltAF, VosMC. A systematic review and meta-analyses of the clinical epidemiology of Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother, 2018; 62(1):e01730–e17; doi: 10.1128/AAC.01730-17
